Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Maria Teresa Voso; Pasquale Niscola; Alfonso Piciocchi; Luana Fianchi; Luca Maurillo; Pellegrino Musto; Livio Pagano; Giovanna Mansueto; Marianna Criscuolo; Maria Antonietta Aloe-Spiriti; Francesco Buccisano; Adriano Venditti; Andrea Tendas; Anna Lina Piccioni; Gina Zini Tanzi; Roberto Latagliata; Nunzio Filardi; Alberto Fragasso; Susanna Fenu; Massimo Breccia

doi:10.1111/ejh.12595

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Maria Teresa Voso, Pasquale Niscola, Alfonso Piciocchi, Luana Fianchi, Luca Maurillo, Pellegrino Musto, Livio Pagano, Giovanna Mansueto, Marianna Criscuolo, Maria Antonietta Aloe-Spiriti, Francesco Buccisano, Adriano Venditti, Andrea Tendas, Anna Lina Piccioni, Gina Zini Tanzi, Roberto Latagliata, Nunzio Filardi, Alberto Fragasso, Susanna Fenu, Massimo Breccia

Risultato della ricerca: Contributo in rivista › Articolo

23 Citazioni (Scopus)

Abstract

Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.

Lingua originale	Inglese
pagine (da-a)	344-351
Numero di pagine	8
Rivista	European Journal of Haematology
DOI	https://doi.org/10.1111/ejh.12595
Stato di pubblicazione	Pubblicato - 2015

Keywords

AML
MDS
azacitidine

Accesso al documento

10.1111/ejh.12595

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Voso, M. T., Niscola, P., Piciocchi, A., Fianchi, L., Maurillo, L., Musto, P., Pagano, L., Mansueto, G., Criscuolo, M., Aloe-Spiriti, M. A., Buccisano, F., Venditti, A., Tendas, A., Piccioni, A. L., Zini Tanzi, G., Latagliata, R., Filardi, N., Fragasso, A., Fenu, S., & Breccia, M. (2015). Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. European Journal of Haematology, 344-351. https://doi.org/10.1111/ejh.12595

@article{063d11ac28944ef188629e7e3b790709,

title = "Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia",

abstract = "Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.",

keywords = "AML, MDS, azacitidine, AML, MDS, azacitidine",

author = "Voso, \{Maria Teresa\} and Pasquale Niscola and Alfonso Piciocchi and Luana Fianchi and Luca Maurillo and Pellegrino Musto and Livio Pagano and Giovanna Mansueto and Marianna Criscuolo and Aloe-Spiriti, \{Maria Antonietta\} and Francesco Buccisano and Adriano Venditti and Andrea Tendas and Piccioni, \{Anna Lina\} and \{Zini Tanzi\}, Gina and Roberto Latagliata and Nunzio Filardi and Alberto Fragasso and Susanna Fenu and Massimo Breccia",

year = "2015",

doi = "10.1111/ejh.12595",

language = "English",

pages = "344--351",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "John Wiley and Sons Inc.",

}

Voso, MT, Niscola, P, Piciocchi, A, Fianchi, L, Maurillo, L, Musto, P, Pagano, L, Mansueto, G, Criscuolo, M, Aloe-Spiriti, MA, Buccisano, F, Venditti, A, Tendas, A, Piccioni, AL, Zini Tanzi, G, Latagliata, R, Filardi, N, Fragasso, A, Fenu, S & Breccia, M 2015, 'Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia', European Journal of Haematology, pagg. 344-351. https://doi.org/10.1111/ejh.12595

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. / Voso, Maria Teresa; Niscola, Pasquale; Piciocchi, Alfonso et al.
In: European Journal of Haematology, 2015, pag. 344-351.

Risultato della ricerca: Contributo in rivista › Articolo

TY - JOUR

T1 - Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

AU - Voso, Maria Teresa

AU - Niscola, Pasquale

AU - Piciocchi, Alfonso

AU - Fianchi, Luana

AU - Maurillo, Luca

AU - Musto, Pellegrino

AU - Pagano, Livio

AU - Mansueto, Giovanna

AU - Criscuolo, Marianna

AU - Aloe-Spiriti, Maria Antonietta

AU - Buccisano, Francesco

AU - Venditti, Adriano

AU - Tendas, Andrea

AU - Piccioni, Anna Lina

AU - Zini Tanzi, Gina

AU - Latagliata, Roberto

AU - Filardi, Nunzio

AU - Fragasso, Alberto

AU - Fenu, Susanna

AU - Breccia, Massimo

PY - 2015

Y1 - 2015

N2 - Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.

AB - Azacitidine is the standard of care for higher-risk myelodysplastic syndromes (MDS). We evaluated factors affecting the outcome of azacitidine treatment in 196 'real-world' patients, retrospectively collected by two Italian cooperative groups.

KW - AML

KW - MDS

KW - azacitidine

KW - AML

KW - MDS

KW - azacitidine

UR - http://hdl.handle.net/10807/73654

U2 - 10.1111/ejh.12595

DO - 10.1111/ejh.12595

M3 - Article

SN - 0902-4441

SP - 344

EP - 351

JO - European Journal of Haematology

JF - European Journal of Haematology

ER -

Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo